Navigation Links
Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference
Date:12/13/2011

SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.  The data are being presented at the 53rd annual American Society of Hematology (ASH) meeting, being held December 10-13, in San Diego, California (Abstract Number: 653; entitled, "FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation"). ProHema is a first-in-class therapeutic candidate, consisting of pharmacologically-enhanced hematopoietic stem cells (HSC), designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies.

The Phase 1b double-UCB study conducted at the Dana-Farber Cancer Institute and the Massachusetts General Hospital achieved its primary objective of demonstrating safety and tolerability of ProHema based upon patient engraftment by Day 42 with greater than 5% chimerism of the ProHema unit. In addition, of the twelve subjects presented in the abstract that received a ProHema unit and an untreated unit, the median time to neutrophil recovery (> 500 cells/uL) was 17.5 days, which compares favorably to a median of 21 days for a historic control group of similarly treated subjects at the Dana-Farber Cancer Institute (n=53).  In addition, the ProHema unit was the dominant source of hematopoiesis in ten of the twelve subjects, suggesting that treatment with ProHema may confer preferential engraftment.

"These clinical trial data support Fate's novel therapeutic approach for the development of stem cell biology-based medici
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. CHEO scientist advances biotherapeutics as published in Cancer Cell
2. Sertoli cells show promise for therapeutics
3. Super-mini vehicles carry therapeutics and imaging agents into body with mega results
4. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
5. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
7. IRSF announces translational research award funding to test potential therapeutics for Rett syndrome
8. AACR, NCI and EORTC to host Molecular Targets and Cancer Therapeutics International Conference
9. Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
10. AACR, NCI and EORTC to host molecular targets and cancer therapeutics conference
11. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... is stored in DNA, tiny strands of nucleic acid ... To express this genetic data, our DNA is copied ... proteins that perform tasks in our cells. , ... RNA molecule. Unlike all other known RNAs, this molecule ... molecules are abundant, little has been known about how ...
(Date:9/18/2014)... Dogs generally seem to be cheerful, happy-go-lucky characters, so ... outlook on life. , In fact some dogs ... University of Sydney shows. , "This research is ... in dogs objectively and non-invasively. It offers researchers and ... and how that changes," said Dr Melissa Starling, from ...
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Dogs can be pessimists too 2Dogs can be pessimists too 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... a new synthetic metabolic pathway for breaking down glucose that ... of biofuels. The new pathway is intended ... series of chemical reactions that nearly all organisms use to ... converts four of the six carbon atoms found in glucose ...
... NASA,s Cassini spacecraft has detected propylene, a chemical used ... products, on Saturn,s moon Titan. This is the ... moon or planet, other than Earth. A small ... by Cassini,s Composite Infrared Spectrometer (CIRS). This instrument measures ...
... 30, 2013 UC Irvine scientists Aaron Esser-Kahn, Sunil ... the prestigious 2013 National Institutes of Health Director,s New ... projects by early-career researchers that show potential to transform ... new ways to improve human health. Esser-Kahn, Gandhi ...
Cached Biology News:UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2NASA's Cassini spacecraft finds ingredient of household plastic in space 2UCI achieves rare trifecta: 3 scientists receive New Innovator Awards 2
(Date:9/18/2014)... September 18, 2014 Bipartisan passage this ... bill designed to stimulate development and commercialization of new ... praised by leaders of SPIE, the international society ... American Manufacturing and Innovation (RAMI) Act, now moves to ... have said they are optimistic that it will win ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
Breaking Biology Technology:House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... - Only Nasal Powder Bird Flu Vaccine Under Development ... No Preservatives - Stable at Room Temperature For 3 Years; No Cold Chain ... ... Bulletin Board: CARN) today announced that its,wholly-owned subsidiary DelSite Biotechnologies, Inc. received a shipment,of ...
... Visits Each Year, East Coast,s Largest Independent Clinical ... ... CEDAR KNOLLS, N.J., Feb. 14 MedeFile,International, Inc. ... medical records management solutions, today announced,that it has signed ...
... Shenzhen Beike,Biotechnology Co., Ltd. ( http://www.beikebiotech.com ... cord stem cells to successfully treat a variety ... Mayor of,Manchester, has returned today to the United ... life-threatening condition known as,cerebellar atrophy. As the latest ...
Cached Biology Technology:Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 2Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 4Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 2Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 4Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 2Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 3
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
...
Biology Products: